How Secreted-embryo-derived Trypsin Initiates, Maintains and Terminates Ca2+ Signals in Uterine Epithelial Cells

Sponsor
ART Fertility Clinics LLC (Other)
Overall Status
Recruiting
CT.gov ID
NCT04865367
Collaborator
University Women's Hospital Tübingen (Other)
30
1
13.8
2.2

Study Details

Study Description

Brief Summary

To develop a deeper understanding of endometrial-embryo crosstalk through basic research, uncover therapeutic targets and to improve reproductive outcome.

Condition or Disease Intervention/Treatment Phase
  • Other: Exposure to culture media

Detailed Description

Pregnancy is a complex and highly coordinated physiological process that involves implantation of a hatched blastocyst into a decidualizing endometrium. The main purpose of implantation is to ensure that the blastocyst firmly anchors into the decidual stroma, which allows further development by enabling placentation. Although a multitude of cellular events and molecular pathways involved in embryo-uterine crosstalk have been identified in mouse models, a comprehensive understanding of human embryo-uterine interaction is still missing. Our work indicates that endometrial epithelial Ca2+ signalling in response to serine proteases released by human embryos plays an important role in maternal recognition and selection of the conceptus at implantation. Previous studies have demonstrated that trophoblast spheroids can elevate [Ca2+]i in human uterine epithelial cell line (Ishikawa) by activating Ca2+ entry via mechano-sensitive Ca2+ permeable channels leading to the induction of epithelial adhesiveness. However, the mechanism(s) mediating the protease-induced [Ca2+]i transients in human uterine epithelium have not been studied to date. Investigators hypothesise that Na+ entry into the intravillous space via trypsin-activated ENaC will depolarise the cellular membrane and increase [Na+]v sufficiently high to reverse the sodium/calcium exchanger providing means for Ca2+ entry into the intravillous space. Ca2+ diffusion from the microvilli into the bulk cytoplasm will increase [Ca2+]i and, in parallel with SOCE, act as a source for re-filling of the ER. Increased [Ca2+]i will also activate the BK channels leading to repolarisation and termination of Ca2+ entry via the NCX.

By using spent medium from embryos, which will undergo pre-implantation genetic testing, it will become possible to determine, whether the above mentioned mechanisms are influenced by the ploidy status of the embryo.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
To Investigate How Secreted-embryo-derived Trypsin Initiates, Maintains and Terminates Ca2+ (Intracellular Calcium) Signals in Uterine Epithelial Cells
Actual Study Start Date :
Nov 4, 2021
Anticipated Primary Completion Date :
Oct 30, 2022
Anticipated Study Completion Date :
Dec 30, 2022

Arms and Interventions

Arm Intervention/Treatment
DEG n1: euploid medium

culture media derived from euploid embryos

Other: Exposure to culture media
Exposure to culture media

DEG n2: aneuploid medium

culture media derived from aneuploid embryos

Other: Exposure to culture media
Exposure to culture media

DEG n3: medium arrested embryos

culture media derived from arrested embryos

Other: Exposure to culture media
Exposure to culture media

DEG n4: control culture medium

pure culture media without contact to embryos

Other: Exposure to culture media
Exposure to culture media

Outcome Measures

Primary Outcome Measures

  1. Change in markers of protein [1 day]

    Change in markers of protein (PAR2, (p) and SGK1, NFkB, ORAI1-3 and STIM1-2 and COX2) using Western blotting

  2. Change in peak and slope levels of intracellular calcium [1 day]

    Change in peak and slope levels of intracellular calcium

  3. Change in morphohology of cells after incubation with embryo media [1 day]

    Change in morphohology of cells after incubation with embryo media

Secondary Outcome Measures

  1. Performance of ICSI [1 day]

    Defined on day 0 as the number of injected oocytes/number of COCs assigned to the ICSI group

  2. Embryo quality on day 3 [1 day]

    Defined by the number of blastomeres and their division pattern, fragmentation, presence of compaction, vacuoles, granulation and nuclei

  3. Embryo quality on day 5 (Gardner and Schoolcraft,1999) [1 day]

    Gardner and Schoolcraft,1999) defined by: The expansion stage of the blastocyst Quality of the ICM and TE Day on which the biopsy is performed (day 5,6 or 7) Pregnancy outcomes (miscarriages/ectopic pregnancy/neonatal outcome)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 36 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Couples with primary / secondary infertility who are planned to undergo ICSI treatment with PGT-A

  • Age of each partner above 18 years

Exclusion Criteria:
  • Couples with consanguinity (couple who is 1st or 2nd degree cousins)

  • Couples in whom the female partner has a history of:

  • Chemotherapy or radiation which impacts the ovarian reserve

  • Surgery at the ovaries / adnex region

  • Endometriosis

  • Couples in whom the male partner has a history of:

  • Chemotherapy / Radiation which impacts the semen result

  • Surgery at the testicles

  • Vasectomy

  • Surgery for reversal of vasectomy

  • Semen obtained by fine needle aspiration (FNA) or Testicular sperm extraction (TESE)

Contacts and Locations

Locations

Site City State Country Postal Code
1 ART Fertility Clinics LLC Abu Dhabi United Arab Emirates 60202

Sponsors and Collaborators

  • ART Fertility Clinics LLC
  • University Women's Hospital Tübingen

Investigators

  • Principal Investigator: BARBARA LAWRENZ, PhD, ART Fertility Clinics LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Barbara Lawrenz, Scientific Director, ART Fertility Clinics LLC
ClinicalTrials.gov Identifier:
NCT04865367
Other Study ID Numbers:
  • 2012-ABU-014-BL
First Posted:
Apr 29, 2021
Last Update Posted:
Feb 18, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Barbara Lawrenz, Scientific Director, ART Fertility Clinics LLC
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 18, 2022